354 related articles for article (PubMed ID: 32899005)
21. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
22. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer.
Chang CL; Yuan KS; Wu SY
Head Neck; 2017 Jul; 39(7):1364-1370. PubMed ID: 28370614
[TBL] [Abstract][Full Text] [Related]
23. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
24. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies.
Petrelli F; Coinu A; Riboldi V; Borgonovo K; Ghilardi M; Cabiddu M; Lonati V; Sarti E; Barni S
Oral Oncol; 2014 Nov; 50(11):1041-8. PubMed ID: 25176576
[TBL] [Abstract][Full Text] [Related]
25. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
26. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y; Biau J; Sun XS; Sire C; Martin L; Alfonsi M; Prevost JB; Modesto A; Lafond C; Tourani JM; Miroir J; Kaminsky MC; Coutte A; Liem X; Chautard E; Vauleon E; Drouet F; Ruffier A; Ramee JF; Waksi G; Péchery A; Wanneveich M; Guigay J; Aupérin A; Bourhis J
Ann Oncol; 2023 Jan; 34(1):101-110. PubMed ID: 36522816
[TBL] [Abstract][Full Text] [Related]
28. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
29. A Network Meta-Analysis of the Systemic Therapies in Unresectable Head and Neck Squamous Cell Carcinoma.
Yuan J; Shi K; Chen G; Xu W; Qiu L; Fei Y; Zhu Y; Wu M; Li Y; Sun X; Cao Y; Zhou S
Cancer Control; 2024; 31():10732748241255535. PubMed ID: 38773761
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
31. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94).
Ghadjar P; Pöttgen C; Joos D; Hayoz S; Baumann M; Bodis S; Budach W; Studer G; Stromberger C; Zimmermann F; Kaul D; Plasswilm L; Olze H; Bernier J; Wust P; Aebersold DM; Budach V
Strahlenther Onkol; 2016 Aug; 192(8):552-60. PubMed ID: 27323753
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
33. Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.
Ou D; Blanchard P; Rosellini S; Levy A; Nguyen F; Leijenaar RTH; Garberis I; Gorphe P; Bidault F; Ferté C; Robert C; Casiraghi O; Scoazec JY; Lambin P; Temam S; Deutsch E; Tao Y
Oral Oncol; 2017 Aug; 71():150-155. PubMed ID: 28688683
[TBL] [Abstract][Full Text] [Related]
34. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Hanemaaijer SH; Kok IC; Fehrmann RSN; van der Vegt B; Gietema JA; Plaat BEC; van Vugt MATM; Vergeer MR; Leemans CR; Langendijk JA; Voortman J; Buter J; Oosting SF
Front Oncol; 2020; 10():761. PubMed ID: 32582534
[No Abstract] [Full Text] [Related]
36. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
[TBL] [Abstract][Full Text] [Related]
37. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
38. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
39. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
40. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
